Overview:

uniQure (Nasdaq: QURE) has been a public company since 2014.

We thank our investors for their support as we advance our gene therapy pipeline toward commercialization.
Contact us at any time.

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease modifying therapies to patients with severe disorders.

We are leveraging our modular and validated technology platform to rapidly advance a focused pipeline of gene therapies.

Stock Quote

Recent News

 

Upcoming Webcast:

There are no upcoming webcasts scheduled

Webcast Archive:

March 15, 2018
Barclays Global Healthcare Conference
Thursday, March 15, 2018
2:05 p.m. ET/ 19:05 CET
Click here to view webcast 

March 14, 2018
Cowen & Company 38th Annual Healthcare Conference
Wednesday, March 14, 2018
08:40 a.m. EST/ 13:40 CET
Click here to view webcast

October 19, 2017
Hemophilia B Gene Therapy Program Update

Thursday, October 19, 2017
08:30 a.m. EDT/ 14:30 CET
Click here to view the recording of the webcast 

 

 Upcoming Events:

 May 16 - 18: World Advanced Therapies & Regenerative Congress 2018, London, United Kingdom.

May 16 - 19: 21st Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT), Chicago, IL.

May 16: Synpromics Scientific Symposium, Chicago, IL.

May 20 - 24: World Federation of Hemophilia (WFH) 2018 World Congress, Glasgow, Scotland.